Analysts Set Celcuity Inc. (NASDAQ:CELC) PT at $30.17

Shares of Celcuity Inc. (NASDAQ:CELC) have received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $30.17.

CELC has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC raised their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th.

Institutional Investors Weigh In On Celcuity

Large investors have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. grew its position in shares of Celcuity by 106.0% during the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock valued at $33,577,000 after acquiring an additional 1,319,700 shares during the period. Shay Capital LLC bought a new stake in shares of Celcuity during the 4th quarter valued at $187,000. Nuveen Asset Management LLC grew its position in shares of Celcuity by 10.8% during the 4th quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company’s stock valued at $911,000 after acquiring an additional 6,785 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company’s stock valued at $258,000 after acquiring an additional 2,756 shares during the period. Finally, J. Goldman & Co LP bought a new stake in shares of Celcuity during the 4th quarter valued at $567,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

Shares of CELC opened at $10.34 on Wednesday. The company has a market capitalization of $383.92 million, a P/E ratio of -3.96 and a beta of 0.65. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $11.66 and a 200 day moving average of $13.45. Celcuity has a twelve month low of $8.53 and a twelve month high of $22.19.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.